Aducanumab

Aducanumab is a human monoclonal antibody that was studied for the treatment of Alzheimer's disease (AD). It was developed by Biogen Inc., which licensed the drug candidate from Neurimmune, its discoverer. The antibody targets aggregated forms of β-amyloid found in the brains of people with Alzheimer’s disease, in the hopes of reducing its buildup. Biogen halted development of the drug in March 2019 after preliminary data from two phase III trials suggested it would not meet the primary endpoint. Aducanumab is a human monoclonal antibody that was studied for the treatment of Alzheimer's disease (AD). It was developed by Biogen Inc., which licensed the drug candidate from Neurimmune, its discoverer. The antibody targets aggregated forms of β-amyloid found in the brains of people with Alzheimer’s disease, in the hopes of reducing its buildup. Biogen halted development of the drug in March 2019 after preliminary data from two phase III trials suggested it would not meet the primary endpoint. Interim results from the second Phase 1 study of the drug were reported in March 2015. A phase Ib study was published in August 2016, based on one year of 'monthly intravenous infusions' of aducanumab, with brain scans to measure amyloid plaques. Phase 3 clinical trials were ongoing in September 2016, but were canceled in March 2019 after 'an independent group's analysis show that the trials were unlikely to 'meet their primary endpoint.''